A 40-year-old woman was diagnosed with Graves' disease in 2001 and treated with thiamazole, but disease control was poor. She was referred to our hospital in 2011 for exacerbation of proteinuria, which had been present since 2006. Urinalysis showed a protein/creatinine ratio of 4.2 g/gCre and microhematuria, and a renal biopsy was performed. On electron microscopy, high electron density deposits were seen on the epithelial side of the glomerular basement membrane. IgG was also deposited along the glomerular loop wall, and membranous nephropathy was diagnosed. Immunostaining revealed thyroid peroxidase deposits but not thyroglobulin antigen deposits, suggesting that the membranous nephropathy was secondary to Graves' disease. The membranous nephropathy improved with I treatment. To our knowledge, this is the first adult case of membranous nephropathy originating from Graves' disease in which deposits of thyroid peroxidase antigens have been detected.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413679 | PMC |
http://dx.doi.org/10.1007/s13730-013-0093-y | DOI Listing |
Indian J Nephrol
June 2024
Department of Radiology, Pondicherry Institute of Medical Sciences, Kalathumettupathai, Kalapet, Pondicherry, India.
An 80-year-old male with a history of prolonged asbestos exposure presented with 24-hour urine protein of 8 gm, and serum albumin of 1.7 gm/dl. Renal biopsy disclosed features of membranous nephropathy.
View Article and Find Full Text PDFIndian J Nephrol
July 2024
Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India.
The simultaneous occurrence of vasculitic glomerulonephritis and membranous nephropathy is unusual. We report two cases that presented to our outpatient department with rapidly progressive renal failure. On evaluation, in one patient, anti-myeloperoxidase (MPO) titers were high, and renal biopsy was suggestive of concurrent necrotizing and diffuse crescentic anti-MPO anti-neutrophil cytoplasmic antigen-associated glomerulonephritis with the circumferential cellular crescent formation and membranous glomerulopathy.
View Article and Find Full Text PDFIndian J Nephrol
July 2024
Department of Nephrology, Base Hospital, New Delhi, Delhi Cantt, India.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody with superior B cell cytotoxicity compared to rituximab. Various case reports suggest that in refractory phospholipase A2 receptor (PLA2R) positive membranous nephropathy (MN) patients, Obinutuzumab led to immunologic remission and improvement in proteinuria. In the present case series, we present six cases of difficult-to-treat PLA2R-associated MN refractory to prednisolone, calcineurin inhibitor (CNI), cyclophosphamide, and rituximab but subsequently responded to Obinutuzumab.
View Article and Find Full Text PDFIndian J Nephrol
October 2024
Department of Nephrology, Sawai Man Singh Medical College, Jaipur, India.
Membranous nephropathy (MN) is a rare autoimmune disease, in which the circulating autoantibodies against antigens attack podocytes. Neural Epidermal Growth Factor like 1 (NELL1) 1-associated MN is the second most common antigen, following phospholipase A2 receptor. Complementary and alternative medicine and malignancies play a pivotal role in the development of NELL1-MN.
View Article and Find Full Text PDFIndian J Nephrol
August 2024
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Background: Viral infections can increase the likelihood of an individual developing membranous nephropathy (MN). Limited information is available regarding the treatment approaches for such cases. We conducted a review focusing on hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV)-associated MN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!